Abstract
Aim:
To search the peroxisome proliferator-activated receptor γ (PPARγ) agonists from Swietenia mahagony extract (SmE) and observe the possible ameliorative effects of SmE on diabetic db/db mice.
Methods:
The PPARγ agonistic activity of SmE was screened by yeast-two hybrid system. The blood glucose levels of diabetic db/db mice were measured using a blood glucose level monitor and the data were statistically analyzed by NDST8.8W software.
Results:
By using the clinical drug rosiglitazone as a positive control, it was found that the PPARγ agonistic activity of SmE at a concentration of 50 μg/L was approximately half that of 35.7 μg/L (0.1 μmol/L) of rosiglitazone. At the dose of 1000 mg/kg, SmE remarkably decreased the blood glucose concentration of db/db mice from (15.26±2.98) to (7.58±2.20) mmol/L, and reduced the blood glucose levels by 55.49% compared with the control group (P<0.01).
Conclusion:
SmE shows agonistic activity to PPARγ and can ameliorate the blood glucose levels of diabetic db/db mice. SmE may be thus used as a potential agent for diabetes therapy.
Similar content being viewed by others
Article PDF
References
Willson TM, Brown PJ, Sternbach DD, Henke BR . The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527–50.
Kerstern S, Desverge B, Wahli W . Roles of PPARs in health and disease. Nature 2000; 405: 421–4.
Escher P, Wahli W . Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutation Res 2000; 448: 121–38.
Vamecq J, Latruffe N . Medical significance of peroxisome proliferator-activated receptors. Lancet 1999; 354: 141–8.
Reginato MJ, Lazar MA . Mechanisms by which thiazolidinediones enhance insulin action. Trends Endoc Metab 1999; 10: 9–13.
Hulin B, McCarthy PA, Gibbs EM . The glitazone family of antidiabetic agents. Curr Pharm Des 1996; 2: 85–102.
Barry GS, William JH . Recent advances in peroxisome proliferator-activated receptor science. Curr Med Chem 2003; 10: 267–80.
Murphy GJ, Holder JC . PPARγ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharm Sci 2000; 21: 469–74.
Shen JH, Xu XY, Cheng F, Liu H, Luo XM, Shen JK, et al. Virtual screening on natural products for discovering active compounds and target information. Curr Med Chem 2003; 10: 2327–42.
Yeast protocol s handbook. Available from: http://www.bdbiosciences.com/clontech/techinfo/manuals/PDF/PT3024-1.pdf.
Chen Q, Chen J, Sun T, Shen JH, Shen X, Jiang HL . A yeast two hybrid technology based system for the discovery of PPARγ agonist and antagonist. Anal Biochem 2004; 335: 253–9.
Taniguchi T, Mizukami J, inventors. Method for identifying or screening agonist and antagonist to PPAR. US patent 6 365 361. 2002 Aug 23.
Kadota S, Marpaaung L, Kikuchi T, Ekimoto H . Constituents of the seeds of Swietenia mahagoni JACQ. III. Structures of mahonin and secomahoganin. Chem Pharm Bull 1990; 38: 1495–500.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Li, Dd., Chen, Jh., Chen, Q. et al. Swietenia mahagony extract shows agonistic activity to PPAR γ and gives ameliorative effects on diabetic db/db mice. Acta Pharmacol Sin 26, 220–222 (2005). https://doi.org/10.1111/j.1745-7254.2005.00527.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00527.x
Keywords
This article is cited by
-
Preliminary investigation into the acute and chronic ingestion of aqueous leaf extract of Swietenia mahagoni (Maliaceae) in rats
Comparative Clinical Pathology (2012)
-
Antibacterial activity of two limonoids from Swietenia mahagoni against multiple-drug-resistant (MDR) bacterial strains
Journal of Natural Medicines (2009)